Core Scientific Shareholders Rejected $9B Sale—Was AMD Deal Worth It?
Core Scientific shareholders blocked a $9B buyout. A new AMD partnership now tests whether that gamble pays off.
Core Scientific shareholders made a high-stakes call when they voted down a $9 billion acquisition offer, betting that the Bitcoin mining and high-performance computing company could generate greater value on its own. That decision now faces a critical stress test as the company moves forward with a significant partnership involving chipmaker AMD, raising questions about whether investors who held the line will ultimately be rewarded.
The rejected buyout would have delivered a substantial and immediate premium to shareholders, the kind of certainty that is rarely available in volatile sectors like cryptocurrency infrastructure and AI-driven data centers. By walking away from that deal, shareholders essentially wagered that Core Scientific's underlying assets — its power capacity, data center footprint, and growing HPC contracts — were worth more than any single acquirer was willing to pay at the time.
Read more Berkshire Hathaway Boosts Alphabet Stake by $17 Billion →
The AMD deal signals that Core Scientific is positioning itself at the intersection of two of the hottest technology trends: artificial intelligence computing demand and next-generation semiconductor deployment. Partnerships with major chip manufacturers can serve as validation of a company's infrastructure quality and long-term relevance, which may help justify the shareholder rebellion against the earlier sale.
Still, the vindication question is far from settled. Shareholders who rejected a guaranteed $9 billion exit now carry the full risk of execution — whether management can convert strategic partnerships into sustained revenue growth and, ultimately, share price appreciation that outpaces what the buyout would have delivered. The AMD collaboration adds credibility, but credibility alone does not close the gap between a bird-in-hand acquisition premium and a longer-term growth thesis.
For now, Core Scientific remains an independent company navigating one of the most competitive and capital-intensive corners of the technology sector. Continue reading at Yahoo Finance.
